Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Glucuronidase beta is an early predictive marker for the use of antidepressant in the treatment of glioma patients

Dayuan Xu, Gang Cui

Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China;

For correspondence:- Gang Cui Email: cui11gang@163.com Tel:+8651265223637

Accepted: 26 September 2022 Published: 28 October 2022

Citation: Xu D, Cui G. Glucuronidase beta is an early predictive marker for the use of antidepressant in the treatment of glioma patients. Trop J Pharm Res 2022; 21(10):2261-2268 doi: 10.4314/tjpr.v21i10.30

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To screen early targets and investigate the potential molecular mechanisms involved in the use of antidepressant in the treatment of glioma.

Methods: The GSE89873 dataset, including expression levels of C6 cells under antidepressant treatment, non-antidepressant drug treatment, and untreated cells (control), was downloaded from database. Differentially expressed genes (DEGs) between antidepressant treatment and untreated cells, and between non-antidepressant drug treatment and untreated cells were identified and annotated. Genes that were significantly related to different drug treatment conditions were screened.

Results: In all, 416 differentially expressed genes (DEGs) were selected between cells of the antidepressant treatment and control groups, while 650 DEGs were selected between cells of the non-antidepressant treatment and control groups. The 402 overlapping DEGs were significantly associated with the apoptotic process, transforming growth factor beta receptor signaling pathway, and cell cycle arrest (p < 0.05). The DEGs ACOX1, ACSL1, GSTM3, and GSTP1 were significantly related to hormonal therapy (p < 0.05). Glucuronidase beta (GUSB) was significantly associated with age and targeted molecular therapy (p < 0.05). The GUSB was also significantly associated with overall survival time (p < 0.05). It is one of the unique DEGs in the antidepressant treatment group that participates in the drug metabolism-cytochrome P450 metabolic pathway.

Conclusion: Glucuronidase beta may be a specific biomarker for the early response of antidepressants to glioma treatment. This should, however, be further investigated to validate this finding.

Keywords: Glioma, Antidepressant treatment, Biomarker